VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+11.92%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$191M
AUM Growth
-$59.3M
(-24%)
Cap. Flow
-$77.9M
Cap. Flow
% of AUM
-40.7%
Top 10 Holdings %
Top 10 Hldgs %
5.8%
Holding
489
New
53
Increased
164
Reduced
226
Closed
46
Top Buys
| 1 |
D.R. Horton
DHI
|
$987K |
| 2 |
Lennar Class A
LEN
|
$952K |
| 3 |
Freeport-McMoran
FCX
|
$917K |
| 4 |
TJX Companies
TJX
|
$909K |
| 5 |
Ametek
AME
|
$905K |
Top Sells
| 1 |
Steel Dynamics
STLD
|
$1.65M |
| 2 |
NOA
North American Construction
NOA
|
$1.55M |
| 3 |
Alamos Gold
AGI
|
$1.53M |
| 4 |
Cheniere Energy
CQP
|
$1.51M |
| 5 |
GTY
Getty Realty Corp
GTY
|
$1.5M |
Sector Composition
| 1 | Healthcare | 26.88% |
| 2 | Financials | 12.6% |
| 3 | Technology | 10.15% |
| 4 | Materials | 9.55% |
| 5 | Real Estate | 8.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Moderna
MRNA
$9.78B
| $260K | 0.14% |
1,448
-492
| -25% | -$88.4K |
|
|
ICPT
302
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $251K | 0.13% |
+20,251
| New | +$251K |
|
|
BLUE
303
DELISTED
bluebird bio
BLUE
| $250K | 0.13% |
+1,807
| New | +$250K |
|
304
Nektar Therapeutics
NKTR
$764M
| $250K | 0.13% |
7,361
+2,560
| +53% | +$86.8K |
|
305
Saratoga Investment
SAR
$395M
| $249K | 0.13% |
9,775
-6,435
| -40% | -$164K |
|
306
Main Street Capital
MAIN
$5.95B
| $246K | 0.13% |
6,658
-251
| -4% | -$9.27K |
|
307
BioNTech
BNTX
$27B
| $244K | 0.13% |
1,626
-121
| -7% | -$18.2K |
|
308
BridgeBio Pharma
BBIO
$10.2B
| $241K | 0.13% |
31,681
-4,494
| -12% | -$34.2K |
|
309
Fidus Investment
FDUS
$757M
| $240K | 0.13% |
12,633
-4,500
| -26% | -$85.6K |
|
|
TSVT
310
DELISTED
2seventy bio
TSVT
| $230K | 0.12% |
+24,598
| New | +$230K |
|
311
Gladstone Investment Corp
GAIN
$543M
| $222K | 0.12% |
17,227
-2,854
| -14% | -$36.8K |
|
312
Algonquin Power & Utilities
AQN
$4.35B
| $220K | 0.11% |
33,698
-81,494
| -71% | -$531K |
|
313
Altimmune
ALT
$334M
| $214K | 0.11% |
+12,993
| New | +$214K |
|
314
Oxford Square Capital
OXSQ
$172M
| $207K | 0.11% |
66,405
+1,360
| +2% | +$4.24K |
|
|
BCIC
315
BCP Investment Corporation Common Stock
BCIC
$160M
| $201K | 0.1% |
8,723
-2,123
| -20% | -$48.8K |
|
316
OFS Capital
OFS
$117M
| $193K | 0.1% |
18,885
-3,330
| -15% | -$34K |
|
|
ILPT
317
Industrial Logistics Properties Trust
ILPT
$407M
| $192K | 0.1% |
58,723
-54,972
| -48% | -$180K |
|
318
SuRo Capital
SSSS
$207M
| $189K | 0.1% |
49,855
+12,038
| +32% | +$45.7K |
|
319
Monroe Capital Corp
MRCC
$164M
| $187K | 0.1% |
21,868
-5,416
| -20% | -$46.3K |
|
320
Avidity Biosciences
RNA
$6.48B
| $182K | 0.1% |
8,215
-637
| -7% | -$14.1K |
|
321
Summit Therapeutics
SMMT
$19.3B
| $182K | 0.1% |
+42,835
| New | +$182K |
|
322
TG Therapeutics
TGTX
$5.11B
| $181K | 0.09% |
15,308
-11,827
| -44% | -$140K |
|
323
Akero Therapeutics
AKRO
$3.58B
| $173K | 0.09% |
3,164
-9,817
| -76% | -$538K |
|
324
Arrowhead Research
ARWR
$4.02B
| $173K | 0.09% |
4,264
+522
| +14% | +$21.2K |
|
325
Zymeworks
ZYME
$1.14B
| $171K | 0.09% |
21,818
+3,838
| +21% | +$30.2K |
|